JaLCDOI 10.18926/AMO/56182
フルテキストURL 72_4_423.pdf
著者 Sakakida, Kourin| Wei, Fan-Yan| Senokuchi, Takafumi| Shimoda, Seiya| Kakuma, Tatsuyuki| Araki, Eiichi| Tomizawa, Kazuhito| The Eperisone for Diabetes with Impaired tRNA (EDIT) Study Group|
抄録 Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1-deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.
キーワード diabetes insulin secretion single nucleotide polymorphism glucose
Amo Type Clinical Study Protocol
発行日 2018-08
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 423
終了ページ 426
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30140092